Alkem Laboratories reported a significant improvement in profitability for the first quarter of fiscal year 2027 (Q1FY27), with standalone net profit rising 48% year-on-year to ₹432.10 crore. The pharmaceutical company’s total income from operations expanded by 25% to ₹3,444.70 crore, reflecting robust demand across its product portfolio. This growth trajectory underscores the company's ability to scale revenues effectively while maintaining healthy margins, a critical factor for investors monitoring the mid-cap pharma segment.

The financial results were filed with the Bombay Stock Exchange and the National Stock Exchange of India Limited on July 30, 2026, pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited figures were scrutinized in accordance with statutory requirements, ensuring transparency for stakeholders ahead of the company’s upcoming annual general meeting.

Financial Performance Highlights

The quarter saw substantial growth across key financial metrics compared to the same period in the previous fiscal year. Standalone net profit before tax stood at ₹581.95 crore, up from ₹391.27 crore in Q1FY26. After-tax net profit reached ₹432.10 crore, a marked increase from ₹287.17 crore recorded twelve months prior. Consolidated net profit also mirrored this trend, rising to ₹450.77 crore from ₹288.30 crore.

Revenue growth was consistent with the previous quarter, where total income was ₹2,941.15 crore, indicating a sequential momentum in sales. The company’s net worth increased to ₹11,580.28 crore as of June 30, 2026, from ₹10,464.11 crore in the same period last year.

Balance Sheet and Debt Dynamics

Alkem Laboratories’ balance sheet showed an increase in outstanding debt, which rose to ₹4,689.82 crore from ₹3,366.15 crore in Q1FY26. Despite the higher debt load, the debt-equity ratio remained manageable at 0.40, up slightly from 0.32 a year ago. The debt service coverage ratio improved significantly to 4.72 from 2.21, suggesting stronger cash flow generation relative to debt obligations.

Interest service coverage ratio declined to 31.21 from 97.83 in the prior year, likely due to the increased interest burden associated with higher debt levels. However, the company maintained a healthy equity share capital of ₹38.66 crore, unchanged from previous periods.

What the Numbers Show

The divergence between revenue growth and the rise in outstanding debt warrants attention. While revenue surged by 25%, debt increased by approximately 39% year-on-year. This suggests that Alkem Laboratories may be leveraging debt to fund expansion or working capital requirements rather than relying solely on internal accruals. However, the robust improvement in the debt service coverage ratio indicates that operating cash flows are sufficient to meet these obligations comfortably, mitigating immediate solvency concerns.

Corporate Governance and Shareholder Updates

In a separate communication, Alkem Laboratories announced that its 52nd Annual General Meeting (AGM) will be held on August 27, 2026, via video conferencing. The meeting will transact business as per the notice dated May 28, 2026. Shareholders holding shares as of the record date, August 20, 2026, are eligible to vote. Remote e-voting will be available from August 24 to August 26, 2026.

The company also fixed August 7, 2026, as the record date for determining dividend entitlements for FY2025-26. If approved by members, the final dividend will be paid on or after September 1, 2026. Investors are advised to submit necessary documents for Tax Deducted at Source (TDS) compliance under the Income-Tax Act, 2025.

Alkem Laboratories reported a 15% year-on-year reduction in its Scope 1 and Scope 2 greenhouse gas emissions for the financial year ended March 31, 2026, marking significant progress toward its voluntary target of a 42% cut by FY 2033 from an FY 2023 baseline. The Mumbai-based pharmaceutical company also recorded a 22% decrease in overall energy consumption, with renewable sources accounting for approximately 27% of its total energy mix during the period.

The disclosure was made under Regulation 34(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, via its Business Responsibility and Sustainability Report (BRSR) for FY26. Deloitte Haskins & Sells LLP provided reasonable assurance on the core indicators of the report. The data reflects standalone operations, noting that the generic business undertaking was transferred to Alkem Wellness Limited effective October 1, 2025.

Environmental Performance

Total Scope 1 and Scope 2 emissions declined to 93,205 tCO2e in FY26, down from 1,09,097 tCO2e in FY25. Scope 1 emissions dropped sharply to 19,088.7 metric tonnes of CO2 equivalent, compared to 33,018 metric tonnes in the previous year. Scope 2 emissions (market-based) were recorded at 74,116.3 metric tonnes of CO2 equivalent, slightly lower than the 76,079 metric tonnes reported in FY25.

Energy efficiency initiatives included the installation of IoT-enabled meters for real-time monitoring and the use of bio-briquettes in boilers as an alternative to fossil fuels. The company achieved ISO 50001 certification across 100% of its operational units. Total energy consumption was 7,54,500 GJ, comprising 2,01,332 GJ from renewable sources and 5,53,168 GJ from non-renewable sources.

Waste and Water Management

Alkem recycled 4,376 metric tonnes of plastic packaging waste under its Extended Producer Responsibility (EPR) framework in FY26, up from 3,961 metric tonnes in FY25. The company recycled or reused 99% of its non-hazardous waste. Total waste generated was 6,228 metric tonnes, of which 5,151 metric tonnes were recycled and 780 metric tonnes underwent other recovery operations.

Water stewardship remains a key priority, with the company targeting water neutrality by FY 2030. Total water withdrawal decreased to 6,19,064 kilolitres from 6,84,761 kilolitres in FY25. Approximately 84% of treated wastewater was reused within facilities for utilities and landscaping. Zero Liquid Discharge systems are operational at 58% of manufacturing units.

Social and Governance Metrics

The company maintained a Lost Time Injury Frequency Rate (LTIFR) of 0.07 per one million person-hours worked for workers, down from 0.09 in FY25. No fatalities were reported. Employee well-being spending constituted 0.2% of total revenue, down from 0.3% in the previous year. Gender diversity in the total workforce stood at 3.39%, with women comprising 17% of the Board of Directors.

What the Numbers Show

The sharp decline in Scope 1 emissions (from 33,018 to 19,088.7 tCO2e) outpaced the reduction in total energy consumption, suggesting that fuel switching—specifically the adoption of bio-briquettes and cleaner fuels—was a more potent driver of decarbonization than pure efficiency gains during FY26. This structural shift in the energy mix aligns with the company’s stated strategy to increase the share of cleaner energy sources.